Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Giessen – page 19

248 clinical trials in Giessen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Giessen at a glance
248
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

248 trials in Giessen

Open in trial search

Acute graft versus host disease

Not recruiting

Study on the Effectiveness of Mesenchymal Stromal Cells in Children with Steroid-Refractory Acute Graft-Versus-Host Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Etanercept
  • Sponsor:Medac Gesellschaft fuer klinische Spezialpraeparate mbH

Study on Rituximab and Drug Combination for Treating Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Abiraterone Acetate
  • Sponsor:Universitaetsklinikum Muenster AöR

Idiopathic pulmonary fibrosis

Not recruiting

Study on the Effects of MBS2320 for Patients with Idiopathic Pulmonary Fibrosis (IPF)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:MBS2320
  • Sponsor:Modern Biosciences Limited

Non-small cell lung cancer metastatic

Not recruiting

Study Comparing MK-7684A with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Glycogen storage disease type II

Not recruiting

Study on the Safety and Efficacy of Cipaglucosidase Alfa and Miglustat for Children with Late-onset Pompe Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Cipaglucosidase Alfa
  • Sponsor:Amicus Therapeutics Inc.

Macular oedema+1

Not recruiting

Study on Ranibizumab Injections and Laser Treatment for Macular Edema in Central Retinal Vein Occlusion Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:Justus-Liebig-Universitaet Giessen

HIV infection

Not recruiting

Study Comparing Integrase Inhibitor (Bictegravir) and Boosted Protease Inhibitor (Darunavir) Treatments for Patients with Advanced HIV Infection

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:NEAT ID Foundation

B-cell type acute leukaemia

Not recruiting

Study on the Safety of Epcoritamab for Children and Young Adults with Relapsed or Refractory Aggressive B-cell Lymphomas

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Hodgkin's disease

Not recruiting

Study of Pembrolizumab with Chemotherapy for Children and Young Adults with Classical Hodgkin Lymphoma Not Responding Well to Initial Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Bleomycin
  • Sponsor:Merck Sharp & Dohme LLC

Pulmonary arterial hypertension

Not recruiting

Study on Seralutinib for Treating Pulmonary Arterial Hypertension in Patients

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Seralutinib
  • Sponsor:GB002 Inc.

Non-small cell lung cancer

Not recruiting

Study of Zipalertinib with Chemotherapy vs. Chemotherapy Alone for Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Taiho Oncology Inc.

Non-small cell lung cancer

Not recruiting

Study of Tuvusertib and Cemiplimab for Patients with Non-Squamous Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Merck Healthcare KGaA

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Giessen

What the registry says about research in the country

01 Respiratory Disease Research

Innovative trials focusing on pulmonary hypertension and lung cancer treatments, including evaluation of novel therapies for various stages of NSCLC and rare pulmonary conditions.

  • Pulmonary Arterial Hypertension
  • Non-Small Cell Lung Cancer
  • Idiopathic Pulmonary Fibrosis

Multiple studies are investigating targeted therapies and combination treatments for advanced lung diseases.

02 Rare Disease Studies

Comprehensive research into rare genetic conditions, including Leber congenital amaurosis and Niemann-Pick disease, with trials testing innovative therapeutic approaches.

  • Ataxia Telangiectasia
  • Spinal Muscular Atrophy
  • Hunter Syndrome

These studies aim to improve treatment options for patients with rare genetic disorders.

03 Oncology Research

Advanced clinical trials examining new treatments for various cancers, particularly focusing on head and neck cancer and innovative immunotherapy combinations.

  • Metastatic Lung Cancer
  • Ovarian Cancer
  • Squamous Cell Carcinoma

Studies are evaluating novel drug combinations and targeted therapies for better treatment outcomes.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.